[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350040-105":59,"doc-detail-350040-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","end-of-life-care-in-advanced-melanoma-a-retrospective-cohort-study-from-an-italian-comprehensive-cancer-center","End-of-life care in advanced melanoma - a retrospective cohort study from an Italian comprehensive cancer center","","End-of-life care in advanced melanoma was assessed through a retrospective cohort study of consecutive patients with advanced skin cancers who died between 2015 and 2021 at a single Italian comprehensive cancer center. The analysis covered systemic therapy, radiotherapy, hospital admissions, emergency department visits, specialist consults, palliative care involvement, and place of death over the last six months. Of 93 patients, most received systemic treatment and imaging was frequent, while palliative care integration remained limited.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/end-of-life-care-in-advanced-melanoma-a-retrospective-cohort-study-from-an-italian-comprehensive-cancer-center/350040/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/end-of-life-care-in-advanced-melanoma-a-retrospective-cohort-study-from-an-italian-comprehensive-cancer-center/350040.png","ImageObject",300,407,{"name":92,"@type":93},"Connor ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main goal of the study?","Question",{"text":113,"@type":114},"To evaluate treatment patterns, healthcare utilization, and the extent of palliative care integration during the last weeks of life in patients with advanced skin cancers, including advanced melanoma.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the cohort defined and what time window was analyzed?",{"text":118,"@type":114},"The study included consecutive patients with advanced skin cancers treated in a single Italian comprehensive cancer center who died between 2015 and 2021, analyzing data from the last six months of life.",{"name":120,"@type":111,"acceptedAnswer":121},"What did the results show about systemic therapy use near end of life?",{"text":122,"@type":114},"Most patients remained on systemic therapy, including a predominance of immune-checkpoint inhibitors, and a large proportion were still receiving active treatment three months before death.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},350040,1790206730,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","De Mattia et al. BMC Cancer (2026) 26:412 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15762-4](https://doi.org/10.1186/s12885-026-15762-4)  \nRESEARCH Open Access  \nEnd-of-life care in advanced melanoma: a retrospective cohort study from an Italian comprehensive cancer center  \nMichela De Mattia 1, Andrea Boutros 1,2*, Virginia Delucchi3, Eva Blondeaux3, Matteo Lambertini1,2, Agostina Lagodin D’Amato 1, Irene Giannubilo1, Lucia Del Mastro 1,2, Paolo Pronzato5, Claudia Bighin5, Francesco Spagnolo1,4,5 and Enrica Teresa Tanda5  \nAbstract  \nBackground Despite improvements in overall survival (OS) with immune-checkpoint inhibitors (ICIs) and targeted therapies, many patients with advanced melanoma and non-melanoma skin cancer still experience disease progression (PD) and remain on systemic therapy during the End of Life (EoL) phase. Evidence on treatment patterns, healthcare utilization, and palliative care integration in the last weeks of life remains scarce.  \nMethods We conducted a retrospective cohort study including consecutive patients with advanced skin cancers treated in a single Italian comprehensive cancer center who died from advanced skin cancer between 2015 and 2021. Data from the last six months of life on systemic therapies, radiotherapy, hospital admissions, emergency department (ED) visits, specialist consults, palliative care, and place of death were analysed. Descriptive statistics and logistic regression were applied to identify predictors of healthcare use.  \nResults A total of 93 patients were included (melanoma n = 84, cutaneous squamous cell carcinoma (CSCC) n = 7, Merkel cell carcinoma (MCC) n = 2) . In the last six months of life, 88 (95%) received systemic therapy, mostly ICIs (n = 66, 71%); among patients with BRAF-mutant melanoma, 33 (72%) received BRAF/MEK inhibitors. At three months before death, 80 (86%) patients remained on active treatment. Imaging was performed frequently, with a median interval between the last CT scan and death of 48 days (interquartile range 26–85) . During the last six months before death, palliative care involvement was limited: 14 (15%) had an outpatient palliative care consult, while 59 (63%) received home-based palliative assistance. Hospitalizations occurred in 55 (59%), and 45 (48%) had ≥ 1 ED visits in the last six months. Home-based palliative care showed a tendency to decrease ED visits (OR 0 .43; 95% CI 0 .13–1. 3; p = 0 . 1) during the last three months of life. Place of death was home for 47 patients (51%), hospital for 32 (34%), and palliative care unit (PCU) for 10 (11%) .  \nConclusion Most patients with advanced cutaneous malignancies remained on systemic therapy until the last  \n12 weeks of life, with high healthcare use and scarce integration of palliative care. These findings underline the  \n*Correspondence:  \nAndrea Boutros [Boutros.andrea@gmail.com](Boutros.andrea@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati","cbCaihFYaH0Lp7Mo","https://ap.wps.com/l/cbCaihFYaH0Lp7Mo","pdf",1122418,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the main goal of the study?\",\"answer\":\"To evaluate treatment patterns, healthcare utilization, and the extent of palliative care integration during the last weeks of life in patients with advanced skin cancers, including advanced melanoma.\"},{\"question\":\"How was the cohort defined and what time window was analyzed?\",\"answer\":\"The study included consecutive patients with advanced skin cancers treated in a single Italian comprehensive cancer center who died between 2015 and 2021, analyzing data from the last six months of life.\"},{\"question\":\"What did the results show about systemic therapy use near end of life?\",\"answer\":\"Most patients remained on systemic therapy, including a predominance of immune-checkpoint inhibitors, and a large proportion were still receiving active treatment three months before death.\"}]","End-of-life care in advanced melanoma - a retrospective cohort study from an Italian comprehensive cancer center | PDF",1790086886,18,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4531a4eb98ea4e498c0351f25de4e90.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c028e455fdd44855f27d00ba723b87bb.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa9735ad8b9abd42a9dfc7798f65c86e.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1365a9bc7a5add46dee6f2c737196164.webp",980,1306]